A hepatokine, FETUB, which is regulated by steatosis and causes glucose intolerance by modulating insulin-independent glucose metabolism and is upregulated in T2D patients37,39, was also significantly downregulated after chiglitazar treatment. The gene discussed is INS; the disease is steatosis.